Abstract
Abstract
Background
The hemodialysis setting is suitable for trials that use cluster randomization, where intact groups of individuals are randomized. However, cluster randomized trials (CRTs) are complicated in their design, analysis, and reporting and can pose ethical challenges. We reviewed CRTs in the hemodialysis setting with respect to reporting of key methodological and ethical issues.
Methods
We conducted a systematic review of CRTs in the hemodialysis setting, published in English, between 2000 and 2019, and indexed in MEDLINE or Embase. Two reviewers extracted data, and study results were summarized using descriptive statistics.
Results
We identified 26 completed CRTs and five study protocols of CRTs. These studies randomized hemodialysis centers (n = 17, 55%), hemodialysis shifts (n = 12, 39%), healthcare providers (n = 1, 3%), and nephrology units (n = 1, 3%). Trials included a median of 28 clusters with a median cluster size of 20 patients. Justification for using a clustered design was provided by 15 trials (48%). Methods that accounted for clustering were used during sample size calculation in 14 (45%), during analyses in 22 (71%), and during both sample size calculation and analyses in 13 trials (42%). Among all CRTs, 26 (84%) reported receiving research ethics committee approval; patient consent was reported in 22 trials: 10 (32%) reported the method of consent for trial participation and 12 (39%) reported no details about how consent was obtained or its purpose. Four trials (13%) reported receiving waivers of consent, and the remaining 5 (16%) provided no or unclear information about the consent process.
Conclusion
There is an opportunity to improve the conduct and reporting of essential methodological and ethical issues in future CRTs in hemodialysis.
Review Registration
We conducted this systematic review using a pre-specified protocol that was not registered.
Funder
Canadian Institutes of Health Research
Heart and Stroke Foundation of Canada
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Medicine (miscellaneous)
Reference78 articles.
1. Strippoli GFM, Craig JC, Schena FP. The number, quality, and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol. 2004;15:411–9.
2. Palmer SC, Sciancalepore M, Strippoli GFM. Trial quality in nephrology: how are we measuring up? Am J Kidney Dis. 2011;58:335–7.
3. Deo A, Schmid CH, Earley A, Lau J, Uhlig K. Loss to analysis in randomized controlled trials in CKD. Am J Kidney Dis. 2011;58:349–55.
4. Inrig JK, Califf RM, Tasneem A, et al. The landscape of clinical trials in nephrology: a systematic review of Clinicaltrials.gov. Am J Kidney Dis. 2014;63:771–80.
5. Kaushalm P, March D, Eborall H, Gray L, Burton J. Poor reporting and conduct of cluster and crossover randomised trials in the haemodialysis population. Nephrol Dialysis Transplant. 2020;35:SO063.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献